The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update
Open accessAbstract
PURPOSE: To update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline. METHODS: An Expert Panel conducted a systematic review to identify new, potentially practice-changing data. RESULTS: Fifty-one articles met eligibility criteria and form the evidentiary basis for the recommendations. RECOMMENDATIONS: Alpelisib in combination with endocrine therapy (ET) should be offered to postmenopausal patients, and to male patients, with HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, ABC, or MBC following prior endocrine therapy with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor. Clinicians should use next-generation sequencing in tumor tissue or cell-free DNA in plasma to detect PIK3CA mutations. If no mutation is found in cell-free DNA, testing in tumor tissue, if available, should be used as this will detect a small number of additional patients with PIK3CA mutations. There are insufficient data at present to recommend routine testing for ESR1 mutations to guide therapy for HR-positive, HER2-negative MBC. For BRCA1 or BRCA2 mutation carriers with metastatic HER2-negative breast cancer, olaparib or talazoparib should be offered in the 1st-line through 3rd-line setting. A nonsteroidal aromatase inhibitor (AI) and a CDK4/6 inhibitor should be offered to postmenopausal women with treatment-naïve HR-positive MBC. Fulvestrant and a CDK4/6 inhibitor should be offered to patients with progressive disease during treatment with AIs (or who develop a recurrence within 1 year of adjuvant AI therapy) with or without one line of prior chemotherapy for metastatic disease, or as first-line therapy. Treatment should be limited to those without prior exposure to CDK4/6 inhibitors in the metastatic setting. Additional information can be found at www.asco.org/breast-cancer-guidelines .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Pain assessment: global use of the Brief Pain Inventory.
Cs, C., & Km, R. (1994) · PubMed · Cited by 5,421
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationAlpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 2×
“Five articles from the biomarkers searches met selection criteria and were included in the systematic review.(3,23,43-45) Biomarker test articles were limited to studies that provided evidence for the clinical utility of the biomarker in question.”
BackgroundMethodSelf-citationTalazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Self-citationRibociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680 · cited 1×
“MONARCH-2 was a double-blind, phase III trial that randomly assigned 669 women with HR-positive, HER2-negative ABC that had progressed on neoadjuvant or adjuvant ET, to abemaciclib plus fulvestrant (n5 446) or to placebo plus fulvestrant (n 5 223).(22) Abemaciclibfulvestrant significantly improved PFS and ORR versus p…”
BackgroundPalbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Sprangers, M. A., Groenvold, M., Arraras, J. I., Franklin, J., te Velde, A., Muller, M., Franzini, L., Williams, A., de Haes, H. C., Hopwood, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2756 · Cited by 1,220
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Simon, R. M., Paik, S., & Hayes, D. F. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp335 · Cited by 1,037
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z. M., Zhang, Q. Y., Martinez Rodriguez, J. L., Campone, M., Hamilton, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02514 · Cited by 1,022
Self-citationOverall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.4782 · Cited by 991
Self-citationHortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy155 · Cited by 876
Overall survival with ribociclib plus fulvestrant in advanced breast cancer
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911149 · Cited by 865
How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis
Shojania, K. G., Sampson, M., Ansari, M. T., Ji, J., Doucette, S., & Moher, D. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-4-200708210-00179 · Cited by 838 · cited 1×
“ASCO uses a signals approach to facilitate guideline updating.(2) This approach identifies new, potentially practice-changing data—signals—that might translate into revised practice recommendations.”
MethodRobson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz012 · Cited by 779
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-018-0097-z · Cited by 685 · cited 1×
“005) in the intent-to-treat population.(18)”
Self-citationRugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L., Fowble, B., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 633
Self-citationAndré, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.011 · Cited by 624 · cited 2×
“Five articles from the biomarkers searches met selection criteria and were included in the systematic review.(3,23,43-45) Biomarker test articles were limited to studies that provided evidence for the clinical utility of the biomarker in question.”
BackgroundMethodSelf-citationPatient-clinician communication: American Society of Clinical Oncology consensus guideline
Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2311 · Cited by 610
Tung, N. M., Robson, M. E., Ventz, S., Santa-Maria, C. A., Nanda, R., Marcom, P. K., Shah, P. D., Ballinger, T. J., Yang, E. S., Vinayak, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02151 · Cited by 508
Duncan, K., Abudu, R., Cira, M. K., & Pyle, D. H. M. (2019) · Journal of Global Oncology · doi:10.1200/jgo.19.11000 · Cited by 480
The Impact of Unconscious Bias in Healthcare: How to Recognize and Mitigate It
Marcelin, J. R., Siraj, D. S., Victor, R., Kotadia, S., & Maldonado, Y. A. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz214 · Cited by 463
Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05125-4 · Cited by 443
Self-citationLitton, J. K., Hurvitz, S. A., Mina, L. A., Rugo, H. S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2098 · Cited by 412
Self-citationVan Poznak, C., Somerfield, M. R., Bast, R. C., Cristofanilli, M., Goetz, M. P., Gonzalez-Angulo, A. M., Hicks, D. G., Hill, E. G., Liu, M. C., Lucas, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1459 · Cited by 404
Self-citationRugo, H. S., Lerebours, F., Ciruelos, E., Drullinsky, P., Ruiz-Borrego, M., Neven, P., Park, Y. H., Prat, A., Bachelot, T., Juric, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00034-6 · Cited by 345
Self-citationGao, J. J., Cheng, J., Bloomquist, E., Sanchez, J., Wedam, S. B., Singh, H., Amiri-Kordestani, L., Ibrahim, A., Sridhara, R., Goldberg, K. B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30804-6 · Cited by 289
Management of Male Breast Cancer: ASCO Guideline
Hassett, M. J., Somerfield, M. R., Baker, E. R., Cardoso, F., Kansal, K. J., Kwait, D. C., Plichta, J. K., Ricker, C., Roshal, A., Ruddy, K. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03120 · Cited by 263
Self-citationVerma, S., Bartlett, C. H., Schnell, P., DeMichele, A. M., Loi, S., Ro, J., Colleoni, M., Iwata, H., Harbeck, N., Cristofanilli, M., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0097 · Cited by 249
Self-citationHarbeck, N., Iyer, S., Turner, N., Cristofanilli, M., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Bhattacharyya, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw139 · Cited by 176
Narayan, P., Prowell, T. M., Gao, J. J., Fernandes, L. L., Li, E., Jiang, X., Qiu, J., Fan, J., Song, P., Yu, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3652 · Cited by 166
Rugo, H. S., Dieras, V. C., Gelmon, K. A., Finn, R. S., Slamon, D. J., Martín, M., Neven, P., Shparyk, Y. V., Mori, A., Lu, D. R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy012 · Cited by 160
Self-citationTurner, N. C., Swift, C., Kilburn, L., Fribbens, C., Beaney, M., Garcia-Murillas, I., Budzar, A. U., Robertson, J. F. R., Gradishar, W., Piccart, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0224 · Cited by 160
Self-citationAre Cancer-Related Decision Aids Effective? A Systematic Review and Meta-Analysis
O'Brien, M. A., Whelan, T. J., Villasis-Keever, M., Gafni, A., Charles, C., Roberts, R., Schiff, S., & Cai, W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.16.0101 · Cited by 159
Loibl, S., Turner, N. C., Ro, J., Cristofanilli, M., Iwata, H., Im, S., Masuda, N., Loi, S., André, F., Harbeck, N., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0072 · Cited by 156
Ettl, J., Quek, R. G. W., Lee, K. H., Rugo, H. S., Hurvitz, S. A., Gonçalvès, A., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martín, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy257 · Cited by 153
Self-citationO’Shaughnessy, J., Petráková, K., Sonke, G. S., Conte, P., Arteaga, C. L., Cameron, D., Hart, L. L., Villanueva, C., Jakobsen, E. H., Beck, J. T., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4518-8 · Cited by 124
Piezzo, M., Chiodini, P., Riemma, M., Cocco, S., Caputo, R., Cianniello, D., Gioia, G. D., Lauro, V. D., Rella, F. D., Fusco, G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176400 · Cited by 119
Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint
Hayes, D. F. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01572 · Cited by 112
Dieras, V. C., Rugo, H. S., Schnell, P., Gelmon, K. A., Cristofanilli, M., Loi, S., Colleoni, M. A., Lu, D. R., Mori, A., Gauthier, E. R., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy109 · Cited by 106
Self-citationTurner, N. C., Finn, R. S., Martín, M., Im, S., DeMichele, A. M., Ettl, J., Dieras, V. C., Moulder, S., Lipatov, O. N., Colleoni, M. A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx797 · Cited by 100
Verma, S., O’Shaughnessy, J., Burris, H. A., Campone, M., Alba, E., Chandiwana, D., Dalal, A. A., Sutradhar, S., Monaco, M., & Janni, W. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4769-z · Cited by 100
Robson, M. E., Ruddy, K. J., Im, S., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Li, W., Tung, N., Armstrong, A. C., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.023 · Cited by 93
Sonke, G. S., Hart, L. L., Campone, M., Erdkamp, F., Janni, W., Verma, S., Villanueva, C., Jakobsen, E. H., Alba, E., Wist, E., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4523-y · Cited by 92
Rugo, H. S., Turner, N. C., Finn, R. S., Joy, A. A., Verma, S., Harbeck, N., Masuda, N., Im, S., Huang, X., Kim, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.017 · Cited by 91
Self-citationHowie, L. J., Singh, H., Bloomquist, E. W., Wedam, S. B., Amiri‐Kordestani, L., Tang, S. W., Sridhara, R., Sanchez, J., Prowell, T. M., Kluetz, P. G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02217 · Cited by 89
Kaufman, P. A., Toi, M., Neven, P., Sohn, J., Grischke, E., Andre, V., Stoffregen, C., Shekarriz, S., Price, G. L., Carter, G. C., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0551 · Cited by 89
Moy, B., Rumble, R. B., Come, S. E., Davidson, N. E., Leo, A. D., Gralow, J. R., Hortobágyi, G. N., Yee, D., Smith, I. E., Chávez‐MacGregor, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01374 · Cited by 81
Harbeck, N., Franke, F. A., Villanueva-Vázquez, R., Lu, Y., Tripathy, D., Chow, L. W., Babu, G. K., Im, Y., Chandiwana, D., Gaur, A., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920943065 · Cited by 75
Messina, C. G. M., Cattrini, C., Buzzatti, G., Cerbone, L., Zanardi, E., Messina, M., & Boccardo, F. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4901-0 · Cited by 74
Goetz, M. P., Martín, M., Tokunaga, E., Park, I. H., Huober, J., Toi, M., Stoffregen, C., Shekarriz, S., Andre, V., Gainford, M. C., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0084 · Cited by 63
Self-citationJanni, W., Alba, E., Bachelot, T., Diab, S., Gil‐Gil, M., Beck, T., Ryvo, L., López‐López, R., Tsai, M. L., Esteva, F. J., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4658-x · Cited by 49
Li, J., Fu, F., Yu, L., Huang, M., Lin, Y., Mei, Q., Lv, J., & Wang, C. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05528-2 · Cited by 47
Rozenblit, M., Mun, S., Soulos, P. R., Adelson, K. B., Pusztai, L., & Mougalian, S. S. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01394-y · Cited by 46
Yanez, B. R., Stanton, A. L., & Maly, R. C. (2012) · Health Psychology · doi:10.1037/a0028629 · Cited by 43
Ciruelos, E., Rugo, H. S., Mayer, I. A., Lévy, C., Forget, F., Mingorance, J. I. D., Safra, T., Masuda, N., Park, Y. H., Juric, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01139 · Cited by 38
Self-citationDeng, Y., Ma, G., Li, W., Wang, T. I., Zhao, Y., & Wu, Q. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.04.017 · Cited by 36
Herrmann, A., Mansfield, E. L., Hall, A. E., Sanson‐Fisher, R., & Zdenkowski, N. (2016) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-016-0273-8 · Cited by 29
Zheng, J., Wu, J., Wang, C., Zhuang, S., Chen, J., & Ye, F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233571 · Cited by 27
Fallowfield, L. J., Catt, S. L., May, S. F., Matthews, L., Shilling, V. M., Simcock, R., Westwell, S., & Jenkins, V. A. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-016-3408-7 · Cited by 25
Self-citationThe CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis
Ding, W., Li, Z., Wang, C., Ruan, G., Chen, L., & Tu, C. (2018) · Medicine · doi:10.1097/md.0000000000010746 · Cited by 16
Cited by
Bidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00338 · Cited by 777
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Bardia, A., Hu, X., Dent, R., Yonemori, K., Barrios, C. H., O’Shaughnessy, J. A., Wildiers, H., Pierga, J.-Y., Zhang, Q., Saura, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2407086 · Cited by 485
Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
Bedrosian, I., Somerfield, M. R., Achatz, M. I., Boughey, J. C., Curigliano, G., Friedman, S., Kohlmann, W. K., Kurian, A. W., Laronga, C., Lynce, F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02225 · Cited by 216
“18 Elsewhere, 19,20 ASCO has addressed the use of biomarker results to inform the use of PARP inhibitors in patients with PALB2 PVs and hormone receptor – positive, HER2-negative MBC.”
BackgroundSelf-citationCristofanilli, M., Rugo, H. S., Im, S.-A., Slamon, D. J., Harbeck, N., Bondarenko, I., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0305 · Cited by 207
Self-citationBardia, A., Krop, I. E., Kogawa, T., Juric, D., Tolcher, A. W., Hamilton, E. P., Mukohara, T., Lisberg, A., Shimizu, T., Spira, A. I., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01909 · Cited by 188
Metadata
- Authors
- Burstein, H. J., Somerfield, M. R., Barton, D. L., Dorris, A., Fallowfield, L. J., Jain, D., Johnston, S. R. D., Korde, L. A., Litton, J. K., Macrae, E. R., Peterson, L. L., Vikas, P., Yung, R. L., & Rugo, H. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-12-10
- Volume
- 39
- Issue
- 35
- Pages
- 3959-3977
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3184794943
- Cited by
- 317
- References
- 69
- FWCI
- 27.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.